SCHEMBL8667929

SCHEMBL8667929

[CH2]CCC=C(Cc1ccccc1)Cc1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES1 P23141 3/20 0.41
CES2 O00748 2/20 0.41
AKR1B1 P15121 1/20 0.41
BTN3A1 O00481 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
HDAC8 Q9BY41 1/20 0.36
HDAC6 Q9UBN7 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2C9 P11712 1/20 0.36
TSHR P16473 1/20 0.36
FNTA P49354 1/20 0.35
FNTB P49356 1/20 0.35
MAOB P27338 1/20 0.34
ALDH1A1 P00352 1/20 0.34
MAPK1 P28482 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
CTBP2 P56545 1/20 0.34
EPHX2 P34913 1/20 0.34
TDP1 Q9NUW8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8668128 0.83 CES1 (0.44) CES1CES2AKR1B1BTN3A1MEN1
SCHEMBL11277665 0.76 CES1 (0.46) CES1CES2AKR1B1BTN3A1MEN1
SCHEMBL9631890 0.76 MAOB (0.50) CES1CES2AKR1B1BTN3A1MEN1
SCHEMBL516676 0.74 CES1 (0.44) CES1CES2AKR1B1BTN3A1MEN1
SCHEMBL11795616 0.73 MEN1 (0.47) MEN1KMT2AMAPK1EPHX2
Bromide SCHEMBL11619427 0.72 CES1 (0.43) CES1CES2AKR1B1BTN3A1MEN1
SCHEMBL5676720 0.72 CES2 (0.39) CES1CES2AKR1B1BTN3A1MEN1
SCHEMBL4246908 0.72 ALDH1A1 (0.44) CES1CES2AKR1B1MEN1KMT2A
SCHEMBL433490 0.70 CES1 (0.44) CES1CES2AKR1B1MEN1KMT2A
SCHEMBL7736497 0.70 SIGMAR1 (0.47)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5811422-A USEFUL FOR TREATING VIRAL INFECTIONS THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) 1998-09-22 US disclosed
US-5610294-A VIRAL TREATMENT THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1997-03-11 US disclosed